Screening multiple endocrine neoplasia type 2A families using DNA markers

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Tumori·2025

PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)].

Cancer treatment reviews·2025

Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells.

Human gene therapy·2019

Host and symbiont intraspecific variability: The case of Paramecium calkinsi and "Candidatus Trichorickettsia mobilis".

European journal of protistology·2017

A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Obesity in the childhood: a link to adult hypertension.

Current pharmaceutical design·2009

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

Molecular therapy. Oncology·2026

In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing.

Molecular therapy. Advances·2026

m6A-dependent regulation of DGUOK-AS1 by RBM15 and HNRNPH1 in lung adenocarcinoma.

iScience·2026

Metabolic reprogramming in pancreatic cancer: interplay of glucose, lipid, and amino acid metabolism in tumor progression.

Cytotechnology·2026

Baicalein targets the Nrf2/Keap1 interaction and related stress pathways to mitigate drug-induced toxicity and reverse resistance in breast cancer: A review.

International journal of biological macromolecules·2026

Exosomes as next-generation drug carriers: Transforming cancer therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026

Related Experiment Videos

Screening multiple endocrine neoplasia type 2A families using DNA markers

Related Concept Videos

The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives.

Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells.

Host and symbiont intraspecific variability: The case of Paramecium calkinsi and "Candidatus Trichorickettsia mobilis".

A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.

Obesity in the childhood: a link to adult hypertension.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.

In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing.

m6A-dependent regulation of DGUOK-AS1 by RBM15 and HNRNPH1 in lung adenocarcinoma.

Metabolic reprogramming in pancreatic cancer: interplay of glucose, lipid, and amino acid metabolism in tumor progression.

Baicalein targets the Nrf2/Keap1 interaction and related stress pathways to mitigate drug-induced toxicity and reverse resistance in breast cancer: A review.

Exosomes as next-generation drug carriers: Transforming cancer therapy.

Related Experiment Videos

Screening multiple endocrine neoplasia type 2A families using DNA markers

Related Concept Videos

Related Articles